atopica logo

ATOPICA® (cyclosporine oral solution) USP MODIFIED

Capstar logo

Capstar® (nitenpyram)

Cheristin product logo

Cheristin® for cats

Comfortis logo

Comfortis® (spinosad)

EasySpot for Cats logo

EasySpot® (fipronil)

fel-o-guard logo

Fel-O-Guard®

Fel-O-Vax logo

Fel-O-Vax®

Interceptor® (milbemycin oxime)

itrafungol logo

Itrafungol™ (itraconazole oral solution)

Milbemite Logo

MilbeMite® OTIC Solution (milbemycin oxime)

 4C 2016[1]

ONSIOR® Tablets for Cats (robenacoxib)

Onsior Injection Logo

ONSIOR® Injection (robenacoxib)

Program for cats logo

Program® (LUFENURON) 6 Month Injectable for Cats

Rabvac logo

Rabvac®

felovax ultra filled logo

ULTRA™ Fel-O-Vax®

Ultra hybrid logo

ULTRA™ Hybrid

UltraNasal®

Vetspon logo

VETSPON

Zobuxa logo

Zobuxa® (enrofloxacin)

Program for cats logo
Program® (LUFENURON) 6 Month Injectable for Cats

One Dose = 6 months of flea control

Program® (LUFENURON) 6 Month Injectable for Cats provides a full 6 months of continuous flea control.

Long-lasting protection, ultimate convenience, proven record

Program® (LUFENURON) 6 Month Injectable for Cats is:

  • Trusted by veterinarians for over 18 years.1
  • The only injectable for cats that controls flea populations by preventing eggs from developing.
  • Administered at the veterinarian’s office.
  • For cats and kittens 6 weeks of age or older.

To learn more about Program and flea control, talk to your veterinarian.

Indications

PROGRAM 6 Month Injectable for Cats is indicated for use in cats, six weeks of age and older, for the control of flea populations.

Lufenuron controls flea populations by preventing the development of flea eggs and does not kill adult fleas. Concurrent use of insecticides may be necessary for adequate control of adult fleas.

Important Safety Information

Do not use in dogs, as severe local reaction may occur in dogs that is not seen in cats. Safety in reproducing animals has not been established. The following adverse reactions may occur in treated cats: pain on injection, injection site lumps, vomiting, lethargy and anorexia. See product label for full safety information.

1Program Injectable NADA 141-105

Program is a trademark of Eli Lilly and Company or its affiliates.